TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
Glickman, MD, explains that success on a GLP-1 medication is considered a body weight loss of more than 5% after three months of treatment
SEE HOW RETATRUTIDE CAN HELP YOUR WEIGHT LOSS JOURNEY What Is Retatrutide
Cureus 2023
Then verify that information independently
Persistent vomiting can lead to dehydration and potentially acute kidney injury, particularly in older adults or those with existing kidney problems